Profile of von Willebrand factor antigen and von Willebrand factor propeptide in an overall TIA and ischaemic stroke population and amongst subtypes

Autor: SJ Lim, Bridget Egan, Rachel T. McGrath, G. F. Kavanagh, Tara Coughlan, D. J. H. McCabe, W. O. Tobin, James S. O’Donnell, Justin A. Kinsella, Desmond O'Neill, Collins, T. M. Feeley, Raymond P. Murphy, Sean Tierney, Sjx Murphy
Rok vydání: 2017
Předmět:
Male
TOAST Classification
congenital
hereditary
and neonatal diseases and abnormalities
medicine.medical_specialty
Population
030204 cardiovascular system & hematology
Gastroenterology
Brain Ischemia
Endothelial activation
03 medical and health sciences
0302 clinical medicine
Von Willebrand factor
Antigens
CD
hemic and lymphatic diseases
Internal medicine
von Willebrand Factor
medicine
Humans
Prospective Studies
Platelet activation
Protein Precursors
education
Stroke
Aged
education.field_of_study
biology
business.industry
Middle Aged
Flow Cytometry
medicine.disease
Surgery
Stenosis
Neurology
Ischemic Attack
Transient
Case-Control Studies
cardiovascular system
biology.protein
Female
Neurology (clinical)
business
Biomarkers
Platelet Aggregation Inhibitors
030217 neurology & neurosurgery
circulatory and respiratory physiology
Blood sampling
Zdroj: Journal of the Neurological Sciences. 375:404-410
ISSN: 0022-510X
Popis: Introduction Von Willebrand factor propeptide (VWF:Ag II) is proposed to be a more sensitive marker of acute endothelial activation than von Willebrand factor antigen (VWF:Ag). Simultaneous data on VWF:Ag and VWF:Ag II profiles are very limited following TIA and ischaemic stroke. Methods In this prospective, observational, case-control study, plasma VWF:Ag and VWF:Ag II levels were quantified in 164 patients ≤ 4 weeks of TIA or ischaemic stroke (baseline), and then ≥ 14 days (14d) and ≥ 90 days (90d) later, and compared with those from 27 healthy controls. TIA and stroke subtyping was performed according to the TOAST classification. The relationship between VWF:Ag and VWF:Ag II levels and platelet activation status was assessed. Results ‘Unadjusted’ VWF:Ag and VWF:Ag II levels were higher in patients at baseline, 14d and 90d than in controls (p ≤ 0.03). VWF:Ag levels remained higher in patients than controls at baseline (p ≤ 0.03), but not at 14d or 90d after controlling for differences in age or hypertension, and were higher in patients at baseline and 90d after controlling for smoking status (p ≤ 0.04). ‘Adjusted’ VWF:Ag II levels were not higher in patients than controls after controlling for age, hypertension or smoking (p ≥ 0.1). Patients with symptomatic carotid stenosis (N = 46) had higher VWF:Ag and VWF:Ag II levels than controls at all time-points (p ≤ 0.002). There was no significant correlation between platelet activation status and VWF:Ag or VWF:Ag II levels. Conclusions VWF:Ag and VWF:Ag II levels are increased in an overall TIA and ischaemic stroke population, especially in patients with recently symptomatic carotid stenosis. VWF:Ag II was not superior to VWF:Ag at detecting acute endothelial activation in this cohort and might reflect timing of blood sampling in our study.
Databáze: OpenAIRE
Externí odkaz: